GERN peer analysis
Geron (GERN) against its competitors: price, today's move, 1-year return and market value side by side.
GERN and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals | $1.43 | -3.38% | 0.00% | $46.53M |
| COAG Hemab | $41.18 | -0.65% | – | – |
| DMRA Damora Therapeutics | $21.60 | 0.51% | – | – |
| INCY Incyte | $120.04 | -0.29% | 28.41% | $24.54B |
| IPSC Century Therapeutics | $1.48 | 0.68% | 153.82% | – |
| RIGL Rigel Pharmaceuticals | $50.53 | -1.52% | 60.01% | $958.46M |
| SLS SELLAS Life Sciences | $8.57 | 0.23% | 370.88% | $1.95B |
| GERN Geron | $0.93 | 3.88% | -26.26% | $574.63M |
- GERN's peers: ATNM (Actinium Pharmaceuticals), COAG (Hemab), DMRA (Damora Therapeutics), INCY (Incyte), IPSC (Century Therapeutics), RIGL (Rigel Pharmaceuticals), SLS (SELLAS Life Sciences).
Updated 2026-11-03 11:32 UTC